Literature DB >> 1398926

Experimental verocytotoxemia in rabbits.

S E Richardson1, T A Rotman, V Jay, C R Smith, L E Becker, M Petric, N F Olivieri, M A Karmali.   

Abstract

The clinicopathologic effects of intravenously administered purified verocytotoxin 1 (VT1; Shiga-like toxin 1) in 2-kg male rabbits was studied. The 50% lethal dose was 0.2 micrograms of protein per kg of body weight (2 x 10(4) 50% cytotoxic doses per kg). The clinical features included nonbloody diarrhea and a progressive flaccid paresis, usually culminating in death. The histopathology was characterized by edema and hemorrhage in the mucosa and submucosa of the cecum and edema, hemorrhage, and neuronal necrosis in the brain and gray matter of the spinal cord. Thrombotic microangiopathy, the characteristic histopathologic renal lesion in the hemolytic-uremic syndrome, was also found to be the underlying lesion in verocytotoxemic rabbits. To determine the specific distribution of VT1 in rabbit tissues, purified 125I-labelled VT1 was administered intravenously to 20 rabbits (both immunologically naive and VT1-immune rabbits). The highest specific uptake of 125I-VT1 was in the spinal cord, brain, cecum, colon, and small bowel in unimmunized animals but in the liver, spleen, and lungs in immune animals. Immunofluorescent staining of cecal and spinal cord tissues after intravenous administration of VT1 showed evidence of specific vascular endothelial cell binding of the toxin. The striking correlation of the central nervous system and gastrointestinal localization of 125I-VT1 with the sites of known histopathology is consistent with direct toxin-mediated injury to these tissues, initiated by the specific binding of VT1 to the vascular endothelium. We conclude that the vascular damage induced by VT1 in affected rabbit tissues is similar to that seen in the kidneys and other tissues in patients with verocytotoxin-producing Escherichia coli-associated hemolytic-uremic syndrome. This suggests that although the rabbit model fails to replicate human hemolytic-uremic syndrome, it is useful for studying the pathogenesis of the vascular lesions in verocytotoxin-producing E. coli-associated diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1398926      PMCID: PMC257448          DOI: 10.1128/iai.60.10.4154-4167.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  The neurotoxin of Shigella shigae: morphological and functional lesions produced in the central nervous system of rabbits.

Authors:  F A BRIDGWATER; R S MORGAN; K E ROWSON; G P WRIGHT
Journal:  Br J Exp Pathol       Date:  1955-10

2.  Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verocytotoxin 1.

Authors:  J Boulanger; M Petric; C Lingwood; H Law; M Roscoe; M Karmali
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

3.  Encephalitozoonosis (nosematosis) and toxoplasmosis.

Authors:  J A Shadduck; S P Pakes
Journal:  Am J Pathol       Date:  1971-09       Impact factor: 4.307

4.  Measurement of spinal cord blood flow by the microsphere technique.

Authors:  D R Smith; H J Smith; R K Rajjoub
Journal:  Neurosurgery       Date:  1978 Jan-Feb       Impact factor: 4.654

Review 5.  Hemolytic-uremic syndrome. Current concepts and management.

Authors:  J S Fong; J P de Chadarevian; B S Kaplan
Journal:  Pediatr Clin North Am       Date:  1982-08       Impact factor: 3.278

6.  The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections.

Authors:  S E Richardson; M A Karmali; L E Becker; C R Smith
Journal:  Hum Pathol       Date:  1988-09       Impact factor: 3.466

7.  Cerebral infection with Escherichia coli O157:H7 in humans and gnotobiotic piglets.

Authors:  S Tzipori; C W Chow; H R Powell
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

8.  Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli.

Authors:  N A Strockbine; L R Marques; R K Holmes; A D O'Brien
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

9.  Experimental infection of infant rabbits with verotoxin-producing Escherichia coli.

Authors:  C H Pai; J K Kelly; G L Meyers
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

10.  Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511.

Authors:  C K Schmitt; M L McKee; A D O'Brien
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

View more
  56 in total

1.  Bidirectional concentration-dependent effects of tumor necrosis factor alpha in Shigella dysenteriae-related seizures.

Authors:  Yael Yuhas; Abraham Weizman; Shai Ashkenazi
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

2.  Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1.

Authors:  D Reymond; M A Karmali; I Clarke; M Winkler; M Petric
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Localization of potential binding sites for the edema disease verotoxin (VT2e) in pigs.

Authors:  T E Waddell; B L Coomber; C L Gyles
Journal:  Can J Vet Res       Date:  1998-04       Impact factor: 1.310

4.  Immunization with non-toxic variants of Shiga toxin type 2 (Stx2) generates high titers of protective antibodies.

Authors:  E V Loukianov; L A Zacharova; O S Khasanova; F K Khasanov; Yu V Kozlov
Journal:  Dokl Biochem Biophys       Date:  2015-03-13       Impact factor: 0.788

5.  An Escherichia coli O157-specific engineered pyocin prevents and ameliorates infection by E. coli O157:H7 in an animal model of diarrheal disease.

Authors:  Jennifer M Ritchie; Jennifer L Greenwich; Brigid M Davis; Roderick T Bronson; Dana Gebhart; Steven R Williams; David Martin; Dean Scholl; Matthew K Waldor
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

6.  A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity against Shiga-like toxins and EHEC-hemolysin of Escherichia coli O157:H7.

Authors:  R Lissner; H Schmidit; H Karch
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

7.  Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice.

Authors:  J Fujii; T Kita; S Yoshida; T Takeda; H Kobayashi; N Tanaka; K Ohsato; Y Mizuguchi
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Escherichia coli Subtilase Cytotoxin.

Authors:  Adrienne W Paton; James C Paton
Journal:  Toxins (Basel)       Date:  2010-02-01       Impact factor: 4.546

9.  Evaluation of a microplate latex agglutination method (Verotox-F assay) for detecting and characterizing verotoxins (Shiga toxins) in Escherichia coli.

Authors:  M A Karmali; M Petric; M Bielaszewska
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

10.  Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.

Authors:  Kristin A D Sauter; Angela R Melton-Celsa; Kay Larkin; Megan L Troxell; Alison D O'Brien; Bruce E Magun
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.